MicroSurgical Technology has acquired the glaucoma-related assets of NeoMedix, according to a press release.
The assets include the surgical platforms Trabectome and Goniotome, which are indicated for treatment of pediatric and adult open- or narrow-angle glaucoma, primary or secondary glaucoma, and pseudoexfoliative or non-pseudoexfoliative glaucoma.
Trabectome promotes sustained IOP reduction through electrosurgical ablation to remove the trabecular meshwork. Goniotome excises the trabecular meshwork using serrated blades, while Goniotome I/A helps maintain a stable, clear anterior chamber while improving angle visualization.
“These products provide MST with a solid entry into the MIGS space while we continue to advance our offerings in complex cataract solutions,” Ramin Mojdeh, president of MST, said in the release.